CERTA Therapeutics
2 known investors
Certa Therapeutics is a biotech company developing anti-fibrotic therapies for serious fibrotic diseases such as systemic sclerosis and chronic kidney disease. Its lead candidate, asengeprast (FT011), is an orally available small molecule that has completed a Phase II clinical trial and received Orphan Drug Designation from the FDA and EMA for scleroderma.
BiotechHealthtech
Investors · 2
Frequently asked questions
- What does CERTA Therapeutics do?
- Certa Therapeutics is a biotech company developing anti-fibrotic therapies for serious fibrotic diseases such as systemic sclerosis and chronic kidney disease. Its lead candidate, asengeprast (FT011), is an orally available small molecule that has completed a Phase II clinical trial and received Orphan Drug Designation from the FDA and EMA for scleroderma.
- Who are CERTA Therapeutics's investors?
- CERTA Therapeutics's investors include Stoic VC, UniSeed Pty Ltd..